|
End-of-day quote
Thailand S.E.
15/10/2026
|
5-day change | 1st Jan Change | ||
| 3.620 THB | +1.69% |
|
+5.23% | - |
| 10-16 | EU Medicines Agency Panel Backs CuraTeQ Biologics' Neupogen Biosimilar for Neutropenia | MT |
| 10-15 | Goldman Sachs Adjusts Price Target on Amgen to $481 From $475 | MT |
Company Valuation: Amgen Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 126,718 | 140,139 | 154,142 | 140,103 | 176,250 | 233,818 | - | - |
| Change | - | 10.59% | 9.99% | -9.11% | 25.8% | 32.66% | - | - |
| Enterprise Value (EV) 1 | 151,990 | 169,779 | 207,811 | 188,229 | 221,725 | 275,174 | 269,115 | 264,240 |
| Change | - | 11.7% | 22.4% | -9.42% | 17.8% | 24.11% | -2.2% | -1.81% |
| P/E | 21.9x | 21.7x | 23.1x | 34.5x | 23x | 27.5x | 24.5x | 23.5x |
| PBR | 18.7x | 38.3x | 24.7x | 23.8x | 20.4x | 20.9x | 17x | 13.6x |
| PEG | - | 1.2x | 7.36x | -0.9x | 0.3x | 2.6x | 2x | 5.46x |
| Capitalization / Revenue | 4.88x | 5.32x | 5.47x | 4.19x | 4.8x | 6x | 5.79x | 5.59x |
| EV / Revenue | 5.85x | 6.45x | 7.37x | 5.63x | 6.03x | 7.06x | 6.67x | 6.32x |
| EV / EBITDA | 9.61x | 10.5x | 11.9x | 9.13x | 10.4x | 12.6x | 12.1x | 11.9x |
| EV / EBIT | 12.2x | 13.3x | 15.5x | 12.5x | 13.7x | 16.2x | 15.2x | 14.3x |
| EV / FCF | 18.1x | 19.3x | 28.2x | 18.1x | 27.4x | 24.8x | 18.1x | 16.9x |
| FCF Yield | 5.51% | 5.17% | 3.54% | 5.52% | 3.65% | 4.04% | 5.54% | 5.91% |
| Dividend per Share 2 | 7.04 | 7.76 | 8.52 | 9 | 9.52 | 10.09 | 10.66 | 11.12 |
| Rate of return | 3.13% | 2.95% | 2.96% | 3.45% | 2.91% | 2.33% | 2.46% | 2.57% |
| EPS 2 | 10.28 | 12.11 | 12.49 | 7.56 | 14.23 | 15.75 | 17.65 | 18.41 |
| Distribution rate | 68.5% | 64.1% | 68.2% | 119% | 66.9% | 64% | 60.4% | 60.4% |
| Net sales 1 | 25,979 | 26,323 | 28,190 | 33,424 | 36,751 | 38,965 | 40,357 | 41,810 |
| EBITDA 1 | 15,822 | 16,178 | 17,470 | 20,620 | 21,370 | 21,765 | 22,232 | 22,226 |
| EBIT 1 | 12,424 | 12,761 | 13,399 | 15,028 | 16,203 | 16,946 | 17,758 | 18,506 |
| Net income 1 | 5,893 | 6,552 | 6,717 | 4,090 | 7,711 | 8,540 | 9,426 | 9,983 |
| Net Debt 1 | 25,272 | 29,640 | 53,669 | 48,126 | 45,475 | 41,356 | 35,297 | 30,422 |
| Reference price 2 | 224.97 | 262.64 | 288.02 | 260.64 | 327.31 | 432.49 | 432.49 | 432.49 |
| Nbr of stocks (in thousands) | 563,266 | 533,579 | 535,178 | 537,533 | 538,481 | 540,632 | - | - |
| Announcement Date | 07/02/22 | 31/01/23 | 06/02/24 | 04/02/25 | 03/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 35.96x | 12.96x | 27.14x | 0.55% | 1,120B | |
| 37.4x | 6.3x | 17.74x | 2.09% | 616B | |
| 36.43x | 8.36x | 17.24x | 2.43% | 504B | |
| 20.46x | 4.99x | 12.38x | 2.64% | 367B | |
| 106.52x | 5.95x | 25.12x | 2.33% | 360B | |
| 21.18x | 5.54x | 13.63x | 2.88% | 288B | |
| 21.7x | 4.38x | 12.55x | 2.01% | 258B | |
| 27.46x | 7.06x | 12.64x | 2.33% | 234B | |
| -45.63x | 6.99x | 27.07x | 2.11% | 194B | |
| Average | 29.05x | 6.95x | 18.39x | 2.15% | 437.88B | |
| Weighted average by Cap. | 34.72x | 8.20x | 20.04x | 1.84% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AMGN Stock
- AMGN06 Stock
- Valuation Amgen Inc.
Select your edition
All financial news and data tailored to specific country editions
